Overview

Serp-1 for the Treatment of Acute Coronary Syndrome

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:
0

Participant gender:
All

Summary

Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV of presumed new ST-segment depression in at least 2 contiguous ECG leads OR, angina and per confirmatory angiogram, has been scheduled for percutaneous coronary angioplasty. The primary objective of this study is to evaluate the safety of Serp-1 injection when administered in 3 daily doses to patients undergoing conventional therapy for Acute Coronary Syndrome (ACS) requiring early intervention.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Viron Therapeutics Inc

Criteria

Inclusion Criteria:

- Established diagnosis of unstable angina or NSTEMI with one or more episodes of angina
in the 24 hours before hospital admission

- Scheduled for PCI

Exclusion Criteria:

- CABG within 6 months

- Acute ST elevation, eligible for thrombolysis on initial examination

- Coronary lesions with total thrombotic occlusions

- Current immunosuppressant therapy